Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries
- Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based data storage.
- Funding will advance next-generation technology platform, expand R&D and manufacturing facilities, grow multidisciplinary team, and launch DNA synthesis service.
- Ansa is solving current industry bottlenecks associated with synthesizing complex DNA sequences that are difficult to obtain from existing DNA synthesis providers.
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ansa Biotechnologies today announced it has closed an oversubscribed Series A financing round of $68 million led by Northpond Ventures, with participation from new investors RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital, and existing investors Mubadala Capital, Humboldt Fund, Fifty Years, and Horizons Ventures. The company has raised a total of $82 million from private financings to date.
The funding will be used to accelerate the development of Ansa’s next-generation enzymatic DNA synthesis technology based on polymerase-nucleotide conjugates, build high-throughput synthesizers, and launch its DNA synthesis service. To support this development, Ansa will expand its state-of-the-art R&D and manufacturing facilities and will grow its multidisciplinary team across biochemistry, chemistry, engineering, bioinformatics, and operations.
Ansa is on a mission to streamline the writing of DNA to power the next era of DNA-enabled industries. Currently, DNA is synthesized via a chemical method that has remained mostly unchanged for 40 years and uses harsh conditions that damage the growing molecules, limiting the length and accuracy of the DNA that is produced. Ansa’s novel enzymatic synthesis technology harnesses the power of nature’s machinery to synthesize DNA in an entirely new way that is substantially faster and more accurate than the chemical method.
Since Ansa’s method uses exquisitely precise enzymes instead of harsh chemicals for all steps of the synthesis process, it does not damage the growing DNA as it is made, enabling the direct synthesis of sequences that are hundreds or possibly even thousands of bases long. These long molecules streamline the construction of even longer sequences and greatly facilitate the construction of “complex” sequences that power emerging synthetic biology applications but are difficult for current vendors to produce.
Ansa’s enzyme-based approach will dramatically accelerate innovation across almost every industry enabled by synthetic DNA-- from biologic therapeutics such as antibodies, gene therapies, and cell therapies, to the biomanufacturing of chemicals, materials, foods, and biofuels, and even to futuristic applications such as DNA-based data storage. The technology also has the potential to unlock new areas of life sciences research that have yet to be explored.
“Enzymatic DNA synthesis is rapidly becoming a commercial reality, and I believe we have the most advanced technology in terms of speed, length, and accuracy. We’re excited to have the support of our top-tier investor syndicate led by Northpond Ventures, and we look forward to bringing our enzymatically synthesized DNA to the market,” said Daniel Lin-Arlow, Ph.D., CEO & Co-founder of Ansa Biotechnologies. “To achieve this goal, we will be rapidly expanding our interdisciplinary team to build our synthesizers, scale up production of our reagents, and launch our service.”
“Currently, the ability to write long and complex DNA is a critical bottleneck in the broader life sciences industry. We believe Ansa’s fully enzymatic process of DNA synthesis will usher in a new era in which the delivery of high-quality and more accurate DNA sequences in a timely manner to end users will become the new industry standard,” said Lily Li, Ph.D., Principal at Northpond Ventures. “Northpond is excited to support Ansa who we think will become a leader in the enzymatic DNA synthesis space, and to work alongside the Ansa team to bring this advantaged technology to market.”
“Ansa’s unparalleled enzymatic approach is well poised to set the new standard for DNA synthesis speed and accuracy,” said Patrick Zhang of Horizons Ventures. “We are excited to further our partnership with Ansa to support the development of this powerful technology, addressing synthetic biology’s burning need for improved writing of the DNA code.”
Co-Founders Daniel Lin-Arlow and Sebastian Palluk were the first to describe a practical enzymatic method for the de novo synthesis of DNA sequences. The patented method, published in Nature Biotechnology in 2018, is based on polymerase-nucleotide conjugates that can rapidly extend a DNA molecule by one base at a time. The conjugates, which comprise a template-independent polymerase tethered to a single nucleotide via a linker, offer significant advantages in terms of cost, speed, and flexibility over other enzymatic synthesis approaches based on free nucleotides.
The company’s technology has much wider impact beyond life sciences applications. Last year, the company announced a collaboration with Microsoft to develop a set of enzymatic reagents for sustainable DNA-based data storage, and the company is actively exploring partnerships in other application areas.
About Ansa Biotechnologies
Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods. For more information, visit ansabio.com or follow on Twitter and LinkedIn.
For partnering inquiries or information about Ansa’s early access program, email DNA@ansabio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005242/en/
Source: Ansa Biotechnologies